KP-402 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Tata Power targets 2.8 GW data-centre opportunity pipeline as Rs 15,000cr Mumbai grid plan advances

Fluence wins Vattenfall’s 1 GWh German battery storage contract as shares face pressure

Essar Oil & Gas adds five CBM blocks with 6.6 Tcf of gas in place

Essar Oil & Gas secures five coal-bed methane blocks with 6.6 Tcf gas-in-place potential

Editorial infographic showing an oil refinery at sunset with market-style chart lines and key ExxonMobil Q3 2026 indicators, including a $4.5 billion refining-margin uplift, a $1.3 billion upstream hit from lower liquids prices, a $2.5 billion timing effect, and an October 30, 2026 results date.

ExxonMobil signals $4.5bn refining earnings boost as oil-price pressure hits upstream

Read More

Pharma Industry News

Mirador Therapeutics licenses long-acting KP-301 antibody from Kira Pharmaceuticals to enter ANCA-associated vasculitis

Mirador licenses long-acting anti-C5a antibody KP-301 from Kira, with Phase 1 planned in 2026 and an AAV Phase 2 study targeted for 2027.

July 17, 2026

web analytics